Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

purpura, rheumatoid arthritis, interstitial nephritis, lupus-like syndrome, sarcoidosis, aggravated psoriasis, urticaria, injection site necrosis, vasculitis and phototoxicity.

Additional serious adverse events included hallucinations. bipolar disorder, mania, encephalopathy (usually elderly treated with higher doses of PEGINTRON), hypotension, tachycardia, retinopathy including macular edema, retinal hemorrhage, cotton wool spots, papilledema, ischemic and hemorrhagic cerebrovascular events, bone marrow toxicity (cytopenia and very rarely aplastic anemia), thyroiditis, dental and periodontal disorders, hemorrhagic/ischemic colitis, dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, hepatic failure, increases in serum creatinine in patients with renal insufficiency, acute hypersensitivity (angioedema, bronchoconstriction, anaphylaxis and cutaneous eruptions) and hypertriglyceridemia.

During the course of therapy lasting up to 48 weeks in patients ages 3 through 17 years receiving PEGINTRON/REBETOL combination therapy, weight loss and growth inhibition were common.

Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination regimen reported adverse reactions similar to those previously associated with this regimen during clinical trials of treatment-naive patients.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, an
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Insulet Corporation (NASDAQ: PODD ), the leader ... Insulin Management System, today announced that Dr. ... of Directors. Dr. Hopfield brings more than ... Board. She currently serves as the Vice Chair of ... largest diabetes research center, diabetes clinic, and provider of ...
(Date:7/28/2015)... 2015   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... quarter ended June 30, 2015 on Tuesday, August 4, ... Regulus will host a conference call and webcast ... Daylight Time to discuss its second quarter 2015 financial ...
(Date:7/28/2015)... Mass., July 28, 2015  Psychemedics Corporation (NASDAQ: ... the period ended June 30, 2015.  The Company also ... to shareholders of record as of August 7, 2015 ... be the Company,s 76 th consecutive quarterly dividend. ... June 30, 2015 was $7.0 million versus $7.7 million ...
Breaking Medicine Technology:Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 2Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 3Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Psychemedics Corporation Announces Second Quarter Earnings 2Psychemedics Corporation Announces Second Quarter Earnings 3Psychemedics Corporation Announces Second Quarter Earnings 4Psychemedics Corporation Announces Second Quarter Earnings 5Psychemedics Corporation Announces Second Quarter Earnings 6Psychemedics Corporation Announces Second Quarter Earnings 7Psychemedics Corporation Announces Second Quarter Earnings 8
... Genmab Initiates a Phase I/II Study of Zalutumumab in ... Advanced Head and Neck Cancer., COPENHAGEN, June 24 ... a Phase I/II study of zalutumumab,(HuMax-EGFr(TM)) in combination with ... The study will include a maximum of 36,patients who ...
... Biopharmaceuticals Plc, a,biopharmaceutical company focused on the development ... initiated a Phase II,equivalent study of MRX-4, in ... allergic rhinitis (AR). The two-arm, randomized, multi-dose,double-blind, placebo-controlled ... study is expected to be completed by the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis 2
(Date:7/28/2015)... , ... July 29, 2015 , ... ... Susan Bentley as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation's leading networking organization exclusively for professional women, boasting more ...
(Date:7/28/2015)... ... , ... Every July, since 2007, about 25 pediatric pulmonary hypertension (PH) patients ... television. They go to summer camp. , PH is incurable and life threatening, as ... pushes hard to get blood through arteries in the lungs narrowed by the disease. ...
(Date:7/28/2015)... ... July 28, 2015 , ... Jordan Valley Medical ... With The Guidelines®-Stroke Gold Plus Award for implementing specific quality improvement measures outline ... , The Get With The Guidelines-Stroke program recognizes hospitals that demonstrate at least ...
(Date:7/28/2015)... Hollywood, Fl (PRWEB) , ... July 28, 2015 ... ... opened its new Total Heart Center at Memorial Regional Hospital, providing expert, streamlined ... 19,000-square-foot center will be suited to provide extensive heart services under one roof, ...
(Date:7/28/2015)... Rosa, California (PRWEB) , ... July 28, 2015 , ... Santa Rosa’s The Press Democrat ... year in a row, Dr. Francisco Canales and Dr. Heather Furnas took the top spot ... the community, Dr. Furnas and Dr. Canales are proud to be bestowed such a prestigious ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Susan Bentley, Owner of Women's Wellness Options, Into its VIP Woman of the Year Circle 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 3Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3Health News:Memorial Cardiac And Vascular Institute Centralizes Cardiac Care Through It's New "Total Heart Center" At Memorial Regional Hospital 2Health News:Dr. Canales and Dr. Furnas Honored as Sonoma County’s Best Cosmetic Surgeons 2
... For the sixth year in a row, HireRight, ... screening solutions, has been named to Deloitte’s prestigious ... ranking of the 50 fastest growing technology, media, ... by Deloitte LLP, one of the nation’s leading ...
... SAN FRANCISCO, Oct. 27 Amgen (Nasdaq: AMGN ... WYE ), today announced,that ENBREL is the first biologic ... multiple measures of efficacy in moderate to,severe rheumatoid arthritis ... this analysis, the safety profile remained consistent with,continuous ENBREL ...
... Outlook, Low Stress & No Smoking Contribute to Healthy ... people who have a,positive outlook, lower stress levels, moderate ... no chronic health,conditions are more likely to thrive in ... issue of the Journals of Gerontology, Medical Sciences., ...
... -. Adaptis, a leading business process,outsourcing (BPO) ... Paul Bessembinders has joined the sales team ... efforts in the Western territory.,Bessembinders will report ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ), "Paul ...
... MONTVALE, N.J., Oct. 27 Memory,Pharmaceuticals Corp. (Nasdaq: ... U.S.,Patent No. 7,429,664, which provides composition of matter ... agonists. These,include R3487/MEM 3454 and R4996/MEM 63908, which ... the treatment of cognitive disorders such as,Alzheimer,s disease ...
... worship felines,like pharos; dog people talk to hounds like ... are different -- in marital status, economic,standing and education ... there are some interesting differences,between cat owners and dog ... Veterinary Medical Association (AVMA). "Our surveys show,that single people ...
Cached Medicine News:Health News: HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth 2Health News: HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth 3Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 2Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 3Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 4Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 5Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 6Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 7Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 8Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 9Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 10Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 11Health News:Study Reveals Factors of Exceptional Health in Old Age 2Health News:Study Reveals Factors of Exceptional Health in Old Age 3Health News:Study Reveals Factors of Exceptional Health in Old Age 4Health News:Adaptis Names New Sales Executive 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Cat People vs. Dog People ... They Really are Different 2
... lead family features St. Jude ... The lead is available in ... and silicone (IsoFlex S lead) ... models, and multiple lead lengths, ...
... Veriteq's Refrigerator and Freezer Monitoring ... monitoring system for refrigerators and ... install. Using a building's existing ... Freezer monitoring solution automates the ...
Antiseptic - Antibacterial Sudsing Cleanser...
HIBICLENS' non-drying, low skin irritation potential promotes compliance with the frequent hand washing associated with today's clinical protocols....
Medicine Products: